Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESC-HBR
2023-509868-20-00Phase 3Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Gaetano Martino
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ticagrelor, prasugrel, clopidogrel and aspirin in acute coronary syndrome (ACS), myocardial infarction (MI) and unstable angina (2 arms), sponsored by Azienda Ospedaliera Universitaria Gaetano Martino. Primary endpoint: Incidence of optimal platelet reactivity (OPR) at 14 ±2 days. Planned start May 2024; status: authorised.
02
Drugs
ticagrelorprasugrelclopidogrelaspirin
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)unstable angina
Beyond the preview
Go deeper on 2023-509868-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509868-20-00.